MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
Humanigen Anteile 2011-2026 | HGEN
Anteile Jährlich Humanigen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 89.2 M | 58.5 M | 37 M | 112 M | 94.8 M | 15 M | 9.71 M | 4.13 M | 4.12 M | 3.03 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 112 M | 3.03 M | 42.7 M |
Anteile Vierteljährlich Humanigen
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 M | 119 M | 101 M | 70.7 M | 65.6 M | 64 M | 59.5 M | 58.8 M | 52.7 M | 51.6 M | 43.5 M | 30.2 M | 22.9 M | 22.8 M | 22.6 M | 111 M | 110 M | 110 M | 110 M | 109 M | 49.2 M | 14.9 M | 15 M | 15 M | 15 M | 15 M | 14.9 M | 4.56 M | 4.45 M | 4.45 M | 4.12 M | 4.12 M | 4.12 M | 33 M | 4.12 M | 4.12 M | 33 M | 32.9 M | 24.3 M | 24.2 M | 15.6 M | 7.74 M | 2.12 M | 2.06 M | 2.02 M | 1.99 M | 6.92 M | 6.87 M | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 119 M | 1.99 M | 37.9 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
69.3 M | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
VistaGen Therapeutics
VTGN
|
30.9 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
60.8 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
63.2 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
152 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
20.5 M | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
165 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
748 M | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Zymeworks
ZYME
|
51.6 M | $ 24.18 | -2.07 % | $ 1.25 B | Canada |
 |
AbbVie
ABBV
|
1.77 B | $ 209.4 | -0.83 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
299 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | USA |
 |
Altimmune
ALT
|
88.1 M | $ 3.02 | -5.63 % | $ 266 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.21 | -6.2 % | $ 309 M | Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
131 M | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Aytu BioScience
AYTU
|
6.28 M | $ 2.6 | -2.8 % | $ 16.3 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
192 M | $ 4.29 | -3.6 % | $ 822 M | Canada |